General Information
R&D-Biopharmaceuticals GmbHAm Klopferspitz 19
D-82152 Planegg
Telefon: +49/89/70076490
E-Mail: wolfgang.richter@rdbiopharma.de
Managing Director: Dr. Wolfgang Richter
Handelsregistereintrag: HRB 154366
Gerichtsstand: München
Disclaimer
R&D GmbH has carefully compiled the contents on this web pages and according to the current state of knowledge. Access to and use of this web pages as well as web pages related or connected to this by links are at the user’s own risk. Damage and warranty claims arising from missing or incorrect data are excluded.
R&D GmbH bears no responsibility or liability for damage of any kind, nor for indirect or consequential damage resulting from access to or use of this web pages or web pages related or connected to this by links.
R&D GmbH is the sole owner of all user rights related to the contents of the web pages, unless otherwise indicated. Without the written permission of R&D GmbH it is prohibited to integrate the protected contents published on these web pages into other programs or other web pages or to use them by any other means.
R&D News
Tubulysins / Cytolysins
The recently discovered natural product class of the tubulysins show a very high cytotoxic activity against in vitro and in vivo tumour models, especially against resistant tumour cell lines. >> more
Epothilones
The FDA approved the first epothilone drug (IXEMPRA™) for BMS in October 2007. Further drug candidates of this natural products class are currently investigated in several clinical trials by several companies. >> more
R&D GmbH, Am Klopferspitz 19, D-82152 Planegg-Martinsried © 2010